See also: Peptide receptor radionuclide therapy The group's portfolio of radiopharmaceuticals includes radioactive agents for positron emission tomography ( PET) imaging as well as single-photon emission computed tomography ( SPECT) diagnostic products. Products ĪAA has a portfolio of diagnostic and therapeutic applications and products in the fields of Molecular Imaging and Therapy. In October 2017, Novartis announced that it intended to acquire the company for US$3.9 billion. ĪAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.
History ĪAA was created in 2002 by Italian physicist Stefano Buono to exploit a patent from the European Organization for Nuclear Research ( CERN). On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A. In late October 2017, Reuters announced that Novartis would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium. The group operates in all three segments of nuclear medicine ( PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
Advanced Accelerator Applications ( AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine.
0 kommentar(er)
